BioPorto A/S (CPH: BIOPOR), an in-vitro diagnostics company, announced on Friday that it has entered into a global distribution agreement with Roche (VTX:ROG), under which BioPorto will deliver a neutrophil gelatinase-associated lipocalin (NGAL) test for use on Roche's cobas c 501/c 502 analysers.
Under the terms of the agreement, Roche will have worldwide exclusive distribution rights for the NGAL test adapted for use on Roche's cobas c 501/c 502 systems.
The company said this agreement has significant strategic importance to ensure the expanded availability of NGAL tests, as well as enhancing the awareness of NGAL as a diagnostic marker for acute kidney injury.
BioPorto expects the agreement to generate revenues starting in 2019.
The NGAL Test is CE marked and BioPorto is currently conducting clinical studies to generate data for FDA approval, which is expected later this year.
BioPorto Diagnostics provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT